Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitric Oxide for MRSA Positive Ulcers
NCT00771368Phase 2Terminated
- Sponsor
- Nitric BioTherapeutics
- Start
- Jan 2009
- Primary completion
- May 2009
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nitric oxide in leg ulcer and pressure ulcer, sponsored by Nitric BioTherapeutics. Primary endpoint: Reduction in bacteria at Day 3. Started Jan 2009; status: terminated.
02
Drugs
nitric oxide
03
Conditions
leg ulcerpressure ulcer
Beyond the preview
Go deeper on NCT00771368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00771368.